These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 28450659

  • 1. Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
    Amin Z, Jayalie VF, Rajabto W.
    Acta Med Indones; 2017 Jan; 49(1):79-88. PubMed ID: 28450659
    [Abstract] [Full Text] [Related]

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P, Green JA.
    Cochrane Database Syst Rev; 2016 May 25; (5):CD010383. PubMed ID: 27223332
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
    Zhang Y, Zhang Z, Huang X, Kang S, Chen G, Wu M, Miao S, Huang Y, Zhao H, Zhang L.
    Clin Lung Cancer; 2017 Sep 25; 18(5):e333-e340. PubMed ID: 28462807
    [Abstract] [Full Text] [Related]

  • 5. Epidermal growth factor receptor tyrosine kinase inhibitors in previously treated advanced non-small-cell lung cancer with wild-type EGFR.
    Mitsuoka S, Kawaguchi T, Kubo A, Isa S, Asai K, Uji M, Watanabe T, Sawa K, Yoshimoto N, Oka T, Nakai T, Suzumura T, Tanaka H, Matsuura K, Kimura T, Yoshimura N, Kudoh S, Hirata K.
    Expert Opin Pharmacother; 2016 Sep 25; 17(2):193-203. PubMed ID: 26781399
    [Abstract] [Full Text] [Related]

  • 6. Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
    Takeda M, Okamoto I, Nakagawa K.
    Lung Cancer; 2015 Apr 25; 88(1):74-9. PubMed ID: 25704957
    [Abstract] [Full Text] [Related]

  • 7. Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs.
    Brückl W, Tufman A, Huber RM.
    Expert Rev Anticancer Ther; 2017 Feb 25; 17(2):143-155. PubMed ID: 27898252
    [Abstract] [Full Text] [Related]

  • 8. Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
    Yang Z, Hackshaw A, Feng Q, Fu X, Zhang Y, Mao C, Tang J.
    Int J Cancer; 2017 Jun 15; 140(12):2805-2819. PubMed ID: 28295308
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
    Kashiwabara K, Semba H, Fujii S, Tsumura S.
    Cancer Chemother Pharmacol; 2017 Apr 15; 79(4):705-710. PubMed ID: 28258422
    [Abstract] [Full Text] [Related]

  • 12. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.
    Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L.
    Lung Cancer; 2014 Aug 15; 85(2):230-8. PubMed ID: 24929780
    [Abstract] [Full Text] [Related]

  • 13. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 15; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 14. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.
    J Natl Cancer Inst; 2017 Jun 01; 109(6):. PubMed ID: 28376144
    [Abstract] [Full Text] [Related]

  • 15. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D, Popat S.
    Future Oncol; 2015 Sep 01; 11(18):2525-40. PubMed ID: 26314834
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
    Lee VH, Leung DK, Choy TS, Lam KO, Lam PM, Leung TW, Kwong DL.
    BMC Cancer; 2016 Feb 24; 16():147. PubMed ID: 26911310
    [Abstract] [Full Text] [Related]

  • 17. Afatinib for the treatment of advanced non-small-cell lung cancer.
    Genova C, Rijavec E, Barletta G, Burrafato G, Biello F, Dal Bello MG, Coco S, Truini A, Alama A, Boccardo F, Grossi F.
    Expert Opin Pharmacother; 2014 Apr 24; 15(6):889-903. PubMed ID: 24646054
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
    Burotto M, Manasanch EE, Wilkerson J, Fojo T.
    Oncologist; 2015 Apr 24; 20(4):400-10. PubMed ID: 25795635
    [Abstract] [Full Text] [Related]

  • 20. Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
    van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.
    PLoS One; 2017 Apr 24; 12(8):e0182885. PubMed ID: 28854272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.